Treatment of Lyme disease

Allen C. Steere, Jerry Green, Gordon J. Hutchinson, Daniel Wallace Rahn, Andrew R. Pachner, Robert T. Schoen, Leonard H. Sigal, Elise Taylor, Stephen E. Malawista

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

We compared phenoxymethyl penicillin, erythromycin, and tetracycline, in each instance 250 mg four times a day for 10 days, for the treatment of early Lyme disease (stage 1). None of 39 patients given tetracycline developed major late complications compared with 3 of 40 penicillin-treated patients and 4 of 29 given erythromycin (p = 0.07). However, with all three antibiotic agents, nearly half of patients had minor late symptoms. For neurologic abnormalities (stage 2), 12 patients were treated with high-dose intraveous penicillin, 20 million U a day for 10 days. Pain usually subsided during therapy, but a mean of 7 to 8 weeks was required for complete recovery of motor deficits. For the treatment of established arthritis (stage 3), 20 patients were assigned treatment with intramuscular benzathine penicillin (7.2 million U) and 20 patients received saline. Seven of the 20 penicillin-treated patients (35%) were apparently cured, but all 20 patients given placebo continued to have attacks of arthritis (P < 0.02). Of 20 arthritis patients treated with intravenous penicillin G, 20 million U a day for 10 days, 11 (55%) were apparentely cured. Thus, all 3 stages of Lyme disease can be treated with antibiotic therapy, but some patients with late disease may not respond.

Original languageEnglish (US)
Pages (from-to)352-356
Number of pages5
JournalZentralblatt fur Bakteriologie Mikrobiologie und Hygiene - Abt. 1 Orig. A
Volume263
Issue number3
DOIs
StatePublished - Jan 1 1987
Externally publishedYes

Fingerprint

Lyme Disease
Penicillins
Arthritis
Therapeutics
Erythromycin
Tetracycline
Penicillin G Benzathine
Penicillin V
Anti-Bacterial Agents
Nervous System Malformations
Penicillin G
Placebos
Pain

ASJC Scopus subject areas

  • Immunology

Cite this

Steere, A. C., Green, J., Hutchinson, G. J., Rahn, D. W., Pachner, A. R., Schoen, R. T., ... Malawista, S. E. (1987). Treatment of Lyme disease. Zentralblatt fur Bakteriologie Mikrobiologie und Hygiene - Abt. 1 Orig. A, 263(3), 352-356. https://doi.org/10.1016/S0176-6724(87)80092-5

Treatment of Lyme disease. / Steere, Allen C.; Green, Jerry; Hutchinson, Gordon J.; Rahn, Daniel Wallace; Pachner, Andrew R.; Schoen, Robert T.; Sigal, Leonard H.; Taylor, Elise; Malawista, Stephen E.

In: Zentralblatt fur Bakteriologie Mikrobiologie und Hygiene - Abt. 1 Orig. A, Vol. 263, No. 3, 01.01.1987, p. 352-356.

Research output: Contribution to journalArticle

Steere, AC, Green, J, Hutchinson, GJ, Rahn, DW, Pachner, AR, Schoen, RT, Sigal, LH, Taylor, E & Malawista, SE 1987, 'Treatment of Lyme disease', Zentralblatt fur Bakteriologie Mikrobiologie und Hygiene - Abt. 1 Orig. A, vol. 263, no. 3, pp. 352-356. https://doi.org/10.1016/S0176-6724(87)80092-5
Steere, Allen C. ; Green, Jerry ; Hutchinson, Gordon J. ; Rahn, Daniel Wallace ; Pachner, Andrew R. ; Schoen, Robert T. ; Sigal, Leonard H. ; Taylor, Elise ; Malawista, Stephen E. / Treatment of Lyme disease. In: Zentralblatt fur Bakteriologie Mikrobiologie und Hygiene - Abt. 1 Orig. A. 1987 ; Vol. 263, No. 3. pp. 352-356.
@article{b9ab3e0f1403418ab8033b339c333361,
title = "Treatment of Lyme disease",
abstract = "We compared phenoxymethyl penicillin, erythromycin, and tetracycline, in each instance 250 mg four times a day for 10 days, for the treatment of early Lyme disease (stage 1). None of 39 patients given tetracycline developed major late complications compared with 3 of 40 penicillin-treated patients and 4 of 29 given erythromycin (p = 0.07). However, with all three antibiotic agents, nearly half of patients had minor late symptoms. For neurologic abnormalities (stage 2), 12 patients were treated with high-dose intraveous penicillin, 20 million U a day for 10 days. Pain usually subsided during therapy, but a mean of 7 to 8 weeks was required for complete recovery of motor deficits. For the treatment of established arthritis (stage 3), 20 patients were assigned treatment with intramuscular benzathine penicillin (7.2 million U) and 20 patients received saline. Seven of the 20 penicillin-treated patients (35{\%}) were apparently cured, but all 20 patients given placebo continued to have attacks of arthritis (P < 0.02). Of 20 arthritis patients treated with intravenous penicillin G, 20 million U a day for 10 days, 11 (55{\%}) were apparentely cured. Thus, all 3 stages of Lyme disease can be treated with antibiotic therapy, but some patients with late disease may not respond.",
author = "Steere, {Allen C.} and Jerry Green and Hutchinson, {Gordon J.} and Rahn, {Daniel Wallace} and Pachner, {Andrew R.} and Schoen, {Robert T.} and Sigal, {Leonard H.} and Elise Taylor and Malawista, {Stephen E.}",
year = "1987",
month = "1",
day = "1",
doi = "10.1016/S0176-6724(87)80092-5",
language = "English (US)",
volume = "263",
pages = "352--356",
journal = "International Journal of Medical Microbiology",
issn = "1438-4221",
publisher = "Urban und Fischer Verlag GmbH und Co. KG",
number = "3",

}

TY - JOUR

T1 - Treatment of Lyme disease

AU - Steere, Allen C.

AU - Green, Jerry

AU - Hutchinson, Gordon J.

AU - Rahn, Daniel Wallace

AU - Pachner, Andrew R.

AU - Schoen, Robert T.

AU - Sigal, Leonard H.

AU - Taylor, Elise

AU - Malawista, Stephen E.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - We compared phenoxymethyl penicillin, erythromycin, and tetracycline, in each instance 250 mg four times a day for 10 days, for the treatment of early Lyme disease (stage 1). None of 39 patients given tetracycline developed major late complications compared with 3 of 40 penicillin-treated patients and 4 of 29 given erythromycin (p = 0.07). However, with all three antibiotic agents, nearly half of patients had minor late symptoms. For neurologic abnormalities (stage 2), 12 patients were treated with high-dose intraveous penicillin, 20 million U a day for 10 days. Pain usually subsided during therapy, but a mean of 7 to 8 weeks was required for complete recovery of motor deficits. For the treatment of established arthritis (stage 3), 20 patients were assigned treatment with intramuscular benzathine penicillin (7.2 million U) and 20 patients received saline. Seven of the 20 penicillin-treated patients (35%) were apparently cured, but all 20 patients given placebo continued to have attacks of arthritis (P < 0.02). Of 20 arthritis patients treated with intravenous penicillin G, 20 million U a day for 10 days, 11 (55%) were apparentely cured. Thus, all 3 stages of Lyme disease can be treated with antibiotic therapy, but some patients with late disease may not respond.

AB - We compared phenoxymethyl penicillin, erythromycin, and tetracycline, in each instance 250 mg four times a day for 10 days, for the treatment of early Lyme disease (stage 1). None of 39 patients given tetracycline developed major late complications compared with 3 of 40 penicillin-treated patients and 4 of 29 given erythromycin (p = 0.07). However, with all three antibiotic agents, nearly half of patients had minor late symptoms. For neurologic abnormalities (stage 2), 12 patients were treated with high-dose intraveous penicillin, 20 million U a day for 10 days. Pain usually subsided during therapy, but a mean of 7 to 8 weeks was required for complete recovery of motor deficits. For the treatment of established arthritis (stage 3), 20 patients were assigned treatment with intramuscular benzathine penicillin (7.2 million U) and 20 patients received saline. Seven of the 20 penicillin-treated patients (35%) were apparently cured, but all 20 patients given placebo continued to have attacks of arthritis (P < 0.02). Of 20 arthritis patients treated with intravenous penicillin G, 20 million U a day for 10 days, 11 (55%) were apparentely cured. Thus, all 3 stages of Lyme disease can be treated with antibiotic therapy, but some patients with late disease may not respond.

UR - http://www.scopus.com/inward/record.url?scp=0023139427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023139427&partnerID=8YFLogxK

U2 - 10.1016/S0176-6724(87)80092-5

DO - 10.1016/S0176-6724(87)80092-5

M3 - Article

VL - 263

SP - 352

EP - 356

JO - International Journal of Medical Microbiology

JF - International Journal of Medical Microbiology

SN - 1438-4221

IS - 3

ER -